NEW YORK – Aiforia Technologies said Thursday that it has received CE-IVD marking for its Aiforia Clinical Suite Viewer, which provides clinical decision support to pathologists by applying artificial intelligence to digital histopathological slides.
The Helsinki-based company called the CE mark a "key advancement" toward its goal of offering end-to-end clinical pathology workflow automation.
"With this new CE-IVD marked tool and our five CE-IVD marked AI models, and more to come, we can cater to the pathology lab with a comprehensive suite of automated tools for cancer diagnostics," Aiforia CEO Jukka Tapaninen said in a statement.
Just two weeks ago, Aiforia announced that it had received a CE-IVD mark for an AI model that helps detect progesterone-positive tumor cells. The firm also offers two other CE-marked AI models for breast cancer diagnostics as well as a PD-L1 AI model for detecting and assessing lung cancer.
"Supportive AI tools in cancer diagnostics will augment pathologists' ability in rendering accurate and timely diagnosis to benefit quality patient care," said Marilyn Bui, scientific director of the analytic microscopy core at Moffitt Cancer Center & Research Institute in Tampa, Florida.